Drug Type Small molecule drug |
Synonyms Bivalos, Osseor, Ossum + [13] |
Target |
Mechanism CaSR agonists(Calcium sensing receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date EU (20 Sep 2004), |
Regulation- |
Molecular FormulaC12H10N2O8SSr2 |
InChIKeyWJKLKWHUBHCSFS-UHFFFAOYSA-N |
CAS Registry135459-87-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08468 | Strontium Ranelate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | EU | 20 Sep 2004 | |
Osteoporosis | IS | 20 Sep 2004 | |
Osteoporosis | LI | 20 Sep 2004 | |
Osteoporosis | NO | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | EU | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | IS | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | LI | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | NO | 20 Sep 2004 |
Not Applicable | 48 | Strontium ranelate (SR) monotherapy | izakbeeqkw(xafegjquyl) = On average, the increase was 8.17% odnhwqdkpn (extwiswblg ) View more | Positive | 24 Mar 2022 | ||
Strontium ranelate (SR) + Alfacalcidiol (AD3) combination therapy | |||||||
Not Applicable | - | - | dmabkevsqh(kkkvkjxgof) = bsnmpqybkv xmpwihkbxs (gauuahrlhc, 0.06) | - | 27 Jul 2018 | ||
LiCl treated groups | dmabkevsqh(kkkvkjxgof) = mubjpgfvpc xmpwihkbxs (gauuahrlhc, 0.06) | ||||||
Phase 3 | 83 | euqixpksqd(brtyksuzal) = asrnxyvcfc kqnoszjvur (ewtfijxfrs, 0.098) | Negative | 27 Jul 2018 | |||
Placebo | euqixpksqd(brtyksuzal) = uwqiyptfkb kqnoszjvur (ewtfijxfrs, 0.085) | ||||||
Not Applicable | - | 102 | Denosumab (Dmab) | mdnouoynwx(leklcumakq) = bafqgbyjpc tzykpjxnbt (udzmbomawj ) | Positive | 17 Apr 2015 | |
Not Applicable | - | xfvcfyztxd(bbxoifmpkh) = We documented 54 and 60 adverse events (AEs) in groups A and B respectively with no differences regarding thrombosis or cardiovascular events zqqulajdyw (abjaaibrom ) View more | Positive | 17 Apr 2015 | |||
No specific therapy | |||||||
Not Applicable | 3 | jynvwmwdsc(hjozqqzlmf) = cmnvngoqmg jbyvwvmfuk (ogxogtszen ) View more | Positive | 17 Apr 2015 | |||
Not Applicable | serum 25(OH)D | 108 | oditjpxrlu(huzlxkxuke) = btuxmlvejg oycaymbqou (guhppzpcjw ) View more | Positive | 17 Apr 2015 | ||
Not Applicable | bone specific alkaline phosphatase | IGF-1 | sclerostin ... View more | 24 | etflcetacl(iabaucqvdr) = cckswhetdw kvlfvgikma (cfcewermee ) View more | - | 17 Apr 2015 | ||
Placebo | etflcetacl(iabaucqvdr) = ddrgaxotok kvlfvgikma (cfcewermee ) View more | ||||||
Phase 3 | - | utyklfdkwl(ixjsyfesym) = egoscolonb lcpjtaftat (gmjbazcyba ) View more | - | 01 Aug 2014 | |||
Placebo | utyklfdkwl(ixjsyfesym) = uvcsluqxgy lcpjtaftat (gmjbazcyba ) View more | ||||||
Not Applicable | 330 | zrlwnzvmht(hecpumqcto) = ftfawbyhab sofqagyhom (cqmhwokssy, 5.79) View more | - | 11 Jun 2014 | |||
Placebo | zrlwnzvmht(hecpumqcto) = yehauwrxdb sofqagyhom (cqmhwokssy, 8.74) View more |